Discover the latest updates on the Global Fund's efforts in combating AIDS, Tuberculosis, and Malaria amidst challenges posed ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Peter Sands, head of the Global Fund, warned that climate change and conflict could undermine health improvements. Despite progress, funding concerns persist for 2026-2028 efforts. The 2024 report ...

Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.

The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...

Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

It could be a real breakthrough for people at risk for HIV infection: A shot given every 6 months that reduces their risk by a whopping 96%.

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...

Dismissing Ukraine’s recent invasion of Kursk, the Russian leader said Kyiv made a mistake in trying to force Moscow to divert its forces from the Donbas region. By Marc SantoraAnton ...

The analyst from RBC Capital noted the impressive efficacy of Gilead's lenacapavir in the PURPOSE-1 PrEP study, which has led to a rise in the company's stock. Further analysis of HIV PrEP studies ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...